Comparative Pharmacology
Head-to-head clinical analysis: LYBALVI versus ZIPRASIDONE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYBALVI versus ZIPRASIDONE HYDROCHLORIDE.
LYBALVI vs ZIPRASIDONE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LYBALVI is a combination of olanzapine and samidorphan. Olanzapine is an atypical antipsychotic with high affinity for serotonin 5-HT2A and 5-HT2C, dopamine D1-D4, histamine H1, and alpha1-adrenergic receptors. Samidorphan is an opioid receptor antagonist with high affinity for mu-opioid receptors, hypothesized to reduce olanzapine-associated weight gain by blocking opioid receptors in the central nervous system.
Ziprasidone is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT2C, 5-HT1D, and alpha1-adrenergic receptors, and has moderate affinity for histamine H1 and alpha2-adrenergic receptors. It exhibits partial agonism at 5-HT1A receptors.
Olanzapine 10 mg / samidorphan 10 mg orally once daily.
20 mg PO BID with food, titrated up to max 80 mg PO BID; IM: 10-20 mg q2h or q4h, max 40 mg/day
None Documented
None Documented
Terminal half-life ~20-30 hours; supports once-daily dosing.
Terminal elimination half-life is approximately 7 hours (range 6–10 hours) for oral administration; clinically, steady state is achieved within 1–3 days.
Renal: ~50% as unchanged drug and metabolites; Fecal: ~40%; Biliary: minor.
Primarily hepatic metabolism via aldehyde oxidase and CYP3A4; <1% excreted unchanged in urine, approximately 20% in feces as metabolites.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic